BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) shares traded up 6.6% on Tuesday . The company traded as high as $36.15 and last traded at $35.96. 2,596,130 shares traded hands during trading, a decline of 4% from the average session volume of 2,707,698 shares. The stock had previously closed at $33.73.
Analyst Upgrades and Downgrades
A number of research firms have commented on BBIO. Scotiabank increased their price objective on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the company a "sector outperform" rating in a report on Monday, November 25th. Oppenheimer began coverage on BridgeBio Pharma in a report on Thursday, October 3rd. They issued a "market perform" rating for the company. Evercore ISI boosted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research note on Monday, December 23rd. Bank of America lifted their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, November 25th. Finally, HC Wainwright reissued a "buy" rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a report on Monday, December 16th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $48.08.
View Our Latest Stock Report on BBIO
BridgeBio Pharma Stock Performance
The business's 50 day moving average price is $27.37 and its 200-day moving average price is $26.41. The firm has a market capitalization of $6.45 billion, a PE ratio of -14.15 and a beta of 1.05.
Insider Activity
In other BridgeBio Pharma news, CEO Neil Kumar sold 27,389 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $613,787.49. Following the completion of the transaction, the chief executive officer now owns 4,897,443 shares in the company, valued at $109,751,697.63. The trade was a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Brian C. Stephenson sold 4,156 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $93,135.96. Following the completion of the sale, the chief financial officer now owns 93,758 shares in the company, valued at approximately $2,101,116.78. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 24.66% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Values First Advisors Inc. acquired a new stake in BridgeBio Pharma in the 3rd quarter valued at about $57,000. CWM LLC raised its holdings in BridgeBio Pharma by 132.9% in the third quarter. CWM LLC now owns 3,442 shares of the company's stock valued at $88,000 after acquiring an additional 1,964 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock worth $117,000 after acquiring an additional 1,645 shares during the last quarter. Amalgamated Bank grew its holdings in BridgeBio Pharma by 24.7% during the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company's stock worth $123,000 after acquiring an additional 962 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in BridgeBio Pharma by 17.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company's stock worth $135,000 after acquiring an additional 801 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
